• Molecular NameRifapentine
  • SynonymCyclopentyl rifampin
  • Weight877.045
  • Drugbank_IDDB01201
  • ACS_NO61379-65-5
  • Show 2D model
  • LogP (experiment)5.29
  • LogP (predicted, AB/LogP v2.0)5.87
  • pkaN/A
  • LogD (pH=7, predicted)2.87
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.77
  • LogSw (predicted, AB/LogsW2.0)0.1
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors6
  • No.of HBond Acceptors16
  • No.of Rotatable Bonds6
  • TPSA220.15
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antibiotic drug used in the treatment of tuberculosis.
  • Absorption_valueN/A
  • Absorption (description)Rapidly and well absorbed from the gastrointestinal tract.
  • Caco_2N/A
  • Bioavailability70.0
  • Protein binding97.7
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityHyperuricemia is the most common adverse event in patients received Rifapentine (21.3%). Other side effects reported with frequency more than 5% are increased levels of ALT and AST, Neutropenia, Pyuria, Proteinuria, Lymphopenia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A